Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2014

View Archived Issues

Ebola virus evades the STAT1-mediated immune response

Novel EZH2 inhibitors for diffuse large B-cell lymphoma identified at Pfizer

Isis Pharmaceuticals designs new huntingtin ASOs

Novartis divulges new anti-IL-17A MAbs

German researchers disclose new MAGE A1-recognizing constructs

Discovery of antibacterial compounds with promising activity against Gram-positive pathogens

Novel LXR agonists for the treatment of lipoprotein disorders

INSERM reports new polypeptides for mitochondrial disorders

Swedish group patents new deuterated catecholamine derivatives

DMC recommends initiation of Ruthigen's phase I/II study of RUT-58-60

Patrys plans phase Ib/II study of PAT-SM6 with carfilzomib in multiple myeloma

Pfizer and Merck & Co. to evaluate combination of pembrolizumab and crizotinib

Alkermes initiates phase I trial of the opioid modulator ALKS-7106

NIH supports Sorrento Therapeutics' development of immunotherapy for IPF

BeiGene moves BTK inhibitor BGB-3111 into the clinic

FDA approves Promacta for severe aplastic anemia

Identification of TLR agonists as novel markers for SSc

Innate Pharma's IPH-4102 receives E.U. orphan drug status for cutaneous T-cell lymphoma

EMA accepts for review Cubist's MAA for ceftolozane/tazobactam

Vivolux plans phase I study of VLX-600 for refractory advanced solid tumors

Empagliflozin launched in the U.S. for type 2 diabetes

Adocia launches phase III study of BioChaperone PDGF-BB in diabetic foot ulcers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...